The dispute between the U.S. and China is more than a question of tariffs, says René Buck, CEO of BCI Global. It involves complex matters of intellectual property and re-sourcing.

The trade standoff between the U.S. and China has yet to seriously impact the pharmaceutical and life sciences industries. But as neither side shows signs of backing down, and tariffs continue to be levied on virtually every segment, those sectors are preparing for a major supply-chain disruption.

Yet another chapter in the chaotic Brexit story has been written, with the scheduling of a general election in Britain on December 12, to determine the fate of Prime Minister Boris Johnson and his embattled government. 

More than $1.7 billion in goods cross the border each day from Mexico into the U.S., with more than 70% traveling by truck. For businesses on both sides of the border, getting goods from point A to B can be a complex, confusing and expensive process. 

The decision about whether to keep manufacturing in China or seek other sources must take into account multiple factors, some of them less obvious than others, says Mark Baxa, president and CEO of FerniaCreek LLC.

Suzanne Richer, director of trade advisory practice with Amber Road, sketches out the major trends that are disrupting global supply chains today.

Supply chains don't just need to be visible — they also need to be transparent. Alexis Bateman, director of MIT Sustainable Supply Chains, explains the difference.

While there are similar regulations and overlapping requirements governing both Mexico and U.S. customs import processes, there are drastic differences that savvy shippers should be aware of.